Brief: Ardelyx Resubmits New Drug Application To U.S. Food And Drug Administration For Xphozah® (Tenapanor)
18/04/2023 13:05
April 18 (Reuters) - Ardelyx Inc ARDX.O :
* ARDELYX RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND
DRUG
ADMINISTRATION FOR XPHOZAH® (TENAPANOR)
* ARDELYX INC - ACKNOWLEDGEMENT OF RECEIPT LETTER FROM FDA,
CONFIRMING RESUBMISSION IS COMPLETE, IS EXPECTED IN MID-MAY
Source text for Eikon: ID:nGNX7lMxHW
Further company coverage: ARDX.O
Recent news on Ardelyx
See all newsArdelyx, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ardelyx says Q2 product revenue at record high but IBSRELA revenue below expectations
Brief: Ardelyx Q2 Product Sales USD 118.129 Million
Ardelyx Q1 product revenue rises 38% on IBSRELA growth
Brief: Ardelyx Q1 Product Sales USD 93.373 Million